112 related articles for article (PubMed ID: 28691251)
1. Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1328-1337. PubMed ID: 28691251
[TBL] [Abstract][Full Text] [Related]
2. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
[TBL] [Abstract][Full Text] [Related]
3. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
[TBL] [Abstract][Full Text] [Related]
4. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
Onakpoya IJ; Heneghan CJ; Aronson JK
Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
[TBL] [Abstract][Full Text] [Related]
5. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Nov; 14(1):191. PubMed ID: 27894343
[TBL] [Abstract][Full Text] [Related]
6. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
Crit Rev Toxicol; 2016 Jul; 46(6):477-89. PubMed ID: 26941185
[TBL] [Abstract][Full Text] [Related]
7. Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems.
Aronson JK
Therapie; 2017 Oct; 72(5):555-561. PubMed ID: 28461037
[TBL] [Abstract][Full Text] [Related]
8. Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision.
Craveiro NS; Lopes BS; Tomás L; Almeida SF
Curr Drug Saf; 2020; 15(1):4-12. PubMed ID: 31584381
[TBL] [Abstract][Full Text] [Related]
9. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
[TBL] [Abstract][Full Text] [Related]
10. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
McNaughton R; Huet G; Shakir S
BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
[TBL] [Abstract][Full Text] [Related]
11. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
Lane S; Lynn E; Shakir S
BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
[TBL] [Abstract][Full Text] [Related]
12. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.
Clarke A; Deeks JJ; Shakir SA
Drug Saf; 2006; 29(2):175-81. PubMed ID: 16454545
[TBL] [Abstract][Full Text] [Related]
13. [Medicines withdrawn in other countries due to safety concerns: should they continue to be available in the Argentine pharmaceutical market?].
Buschiazzo H; Dorati C; Iusef Venturini N; Cañas M; Urtasun MA; Marin GH; Prozzi GR; Rivadulla PA; Trionfetti M; Mordujovich Buschiazzo P
Rev Fac Cien Med Univ Nac Cordoba; 2022 Sep; 79(3):241-247. PubMed ID: 36149072
[TBL] [Abstract][Full Text] [Related]
14. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
[TBL] [Abstract][Full Text] [Related]
15. Safety-Related Drug Withdrawals in China Between 1999 and 2021: A Systematic Investigation and Analysis.
Li Y; Jiang Y; Wang H; Zhang L; Yang Y
Drug Saf; 2022 Jul; 45(7):737-745. PubMed ID: 35821561
[TBL] [Abstract][Full Text] [Related]
16. Comparative regulatory performance on introduction & withdrawal of drugs in India and EU/internationally.
Kshirsagar NA; Bachhav SS
Int J Risk Saf Med; 2013; 25(4):235-8. PubMed ID: 24305562
[TBL] [Abstract][Full Text] [Related]
17. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134
[TBL] [Abstract][Full Text] [Related]
18. Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001-2012.
Bouvy JC; Huinink L; De Bruin ML
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1004-14. PubMed ID: 27146035
[TBL] [Abstract][Full Text] [Related]
19. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
20. Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.
Lexchin J
BMJ Open; 2014 Feb; 4(2):e004289. PubMed ID: 24549164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
